|
Palmer
& Dodge LLP We understand the Life Sciences industry. The Palmer
& Dodge Life Sciences Group includes more than 55 lawyers and
patent professionals. We represent over 150 public and private companies
in the biotechnology, medical device and pharmaceutical fields.
As outside counsel, we form teams that draw upon the expertise of
our Business, Patent, Tax, Labor, Litigation, and Real Estate areas
to provide clients with the best possible representation tailored
to their specific strategic needs. Our Life Sciences Group also includes a team of seasoned patent attorneys and post-doctoral level technology specialists who are registered patent agents. As one of the nation's leading law firms in the life sciences field, we have extensive experience with all aspects of intellectual property protection for companies that focus on the biological sciences, including patent protection for inventions relating to genes, gene regulation, proteins and protein interactions, gene and protein therapies and therapeutics, bioinformatics, genomics, proteomics, combinatorial chemistry, pharmaceuticals, drug discovery, immunology and other platform technologies. Our lawyers will guide you every step of the way, from startup to maturity. |
|
|
The American Stock Exchange® (Amex®) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRSSM. In its role as a national equities market, the Amex provides a range of personalized, value-added services tailored to meet the needs of small and mid-cap companies. The Amex is also the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Today, the Amex continues to lead the industry with over 120 listings. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. To learn more, call John McGonegal, Senior Vice President, Equities, at 212-306-1652, or visit www.amex.com |
 |
|
Invest Australia is the Australian Government’s inward investment agency. Since its establishment in 1997, Invest Australia has helped companies invest an estimated US$9 billion and is currently working on projects with potential investment in Australia of more than US$60 billion. In 2004 Australia experienced strong confidence in the biotech sector with 25 new listings on the Australian Stock Exchange (ASX). The number of listings was more than double the number in 2003 when 12 stocks listed in the sector. The return on investment was 23 per cent in 2004. There are now 109 life science stocks in the listed sector in Australia valued at A$21.7 billion. Australia offers good commercial opportunities particularly in oncology, immunology and clinical trials. Invest Australia can provide information on Australia’s
untapped biotech opportunities at all stages of the development
chain, as well as our proven biotechnology strengths. We can help
you to establish a business in Australia; arrange site visits and
link investors with potential joint venture partners. Put Invest Australia to work for you. For more information about the strengths, capabilities and investment opportunities in Australian biotechnology visit: www.investaustralia.com/biotech or contact one of our offices in the USA. New York: +1 212 351 6570 San Francisco: +1 415 243 2071 |
|
| Katan
Associates Your Global Capitalization
Partner Based in the world’s leading centers for biotechnology and biomedicare, Katan Associates brings together specialists from a diverse range of corporate and commercial backgrounds to advise firms on long term growth and capitalization solutions. Katan Associates focuses on five core areas of specialization in helping firms achieve their business growth.
Katan provides businesses and management teams with the tools and the infrastructure to grow and expand their business. To find out more, please visit our website at www.katanassociates.com Or contact Seth Yakatan, Partner, at 323.356.6321 or seth@katanassociates.com |
|
| SWX
Swiss Exchange The SWX Swiss Exchange ranks among the world’s most technologically advanced securities exchanges. Backed by the strength of Switzerland’s financial marketplace, it resolutely pursues an internationally oriented strategy. In transnational collaboration with partner organisations, the SWX Swiss Exchange provides first-rate securities exchange services to all parties involved. Not only is its broad product palette a convincing factor in this regard, but also its fully integrated and totally automated trading, clearing and settlement system that remains unique in the world. The SWX Swiss Exchange offers innovative, international companies access to the Swiss capital market. A public placement of securities in one of its trading segments affords companies a high degree of global visibility among investors. An initial public offering in Switzerland is an attractive opportunity for companies to raise equity capital, especially those in the life science, IT and micro- and nanotechnology industries. SWX Swiss Exchange |
 |